Background—Despite the enhanced properties of the second-generation drug-eluting stent (DES), its association with neoatherosclerosis has not been sufficiently evaluated. Therefore, we sought to evaluate and compare neoatherosclerosis in second-generation DESs to first-generation DESs.

Methods and Results—A total of 212 DES-treated patients with >50% percent neointimal cross-sectional area stenosis were retrospectively enrolled from the Korean multicenter optical coherence tomography (OCT) registry. Within this population, 111 patients had a second-generation DES (40 zotarolimus, 36 everolimus, and 35 biolimus) and 101 patients had a first-generation (65 sirolimus and 36 paclitaxel) DES. Neoatherosclerosis on OCT was defined as neointima formation with the presence of lipids or calcification. OCT-determined neoatherosclerosis was identified in 27.4% (58/212) of all DES-treated lesions. The frequency of neoatherosclerosis increased with the stent age. Stent age was shorter in the second-generation DES group (12.4 months versus 55.4 months, \( P < 0.001 \)), and neoatherosclerosis was less frequently observed in that group (10.8% versus 45.5%, \( P < 0.001 \)). However, after adjusting for cardiovascular risk factors, chronic kidney disease (odds ratio, 4.113; 95% confidence interval, 1.086–15.575; \( P = 0.037 \)), >70 mg/dL of low-density cholesterol at follow-up OCT (odds ratio, 2.532; 95% confidence interval, 1.054–6.084; \( P = 0.038 \)), and stent age (odds ratio, 1.710; 95% confidence interval, 1.403–2.084; \( P < 0.001 \)) were all independent predictors for neoatherosclerosis, whereas the type of DES (first- versus second-generation) was not. Patients with neoatherosclerosis showed a higher rate of acute coronary syndrome at follow-up OCT (19.0% versus 3.9%, respectively, \( P = 0.001 \)).

Conclusions—The second-generation DES is not more protective against neoatherosclerosis compared with the first-generation DES. (Circ Cardiovasc Interv. 2015;8:e001878. DOI: 10.1161/CIRCINTERVENTIONS.114.001878.)

Key Words: atherosclerosis ■ drug-eluting stent ■ optical coherence tomography

According to a previous pathological study using directional coronary atherectomy specimens, the components of neointimal tissue in drug-eluting stent (DES) in-stent restenosis were similar to those of bare-metal stent in-stent restenosis at 4 to 36 months after implantation, and the components were mainly composed of smooth muscle cells.1 Recently, neoatherosclerosis, the atherosclerotic change within neo-intima, has been introduced as an important variable in both ex- and in-vivo studies.2-7 Neoatherosclerosis is observed more frequently and occurs significantly earlier in DES-treated lesions when compared with bare-metal stent-treated lesions.2-7 Furthermore, compared with patients without neoatherosclerosis, those with neoatherosclerosis have more severe coronary artery disease, such as acute coronary syndrome or stent thrombosis.5,7 Accordingly, neoatherosclerosis has been regarded as a primary mechanism for late stent failure after DES implantation.9 From recent registry studies with large study populations, the second-generation DES showed similar efficacy, but lower incidence of stent thrombosis compared with the first-generation DES.10,11 However, the development of neoatherosclerosis in second-generation DESs has not been sufficiently evaluated. Although the previous studies suggested several predictors for neoatherosclerosis, it did not compare first- with second-generation DESs or included....
lesions with a small burden of neointima that were not related to clinical events. Therefore, we sought to investigate the neatherosclerosis in DES-treated lesions with larger burden of neointima and compare first- and second-generation DES-treated lesions using optical coherence tomography (OCT).

WHAT IS KNOWN

- Neoatherosclerosis is observed more frequently and occurs significantly earlier in first-generation drug-eluting stent–treated lesions when compared with bare-metal stent–treated lesions.
- The incidence of neoatherosclerosis increases with stent age.
- The possible predictors for in-stent neoatherosclerosis were usage of first-generation drug-eluting stent, longer stent age, chronic kidney disease, and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker.

WHAT THE STUDY ADDS

- The second-generation DES is not more protective against neoatherosclerosis compared with the first-generation DES.
- More than 70 mg/dL of low-density cholesterol at follow-up was an independent predictor for neoatherosclerosis.

Methods

Study Design and Patients

The Korean multicenter OCT registry consisted of 5 hospitals in South Korea, and it investigated a variety of vascular reactions of the coronary artery after stent implantation. All patients who received postintervention or follow-up OCT evaluation after stent implantation were eligible for this registry. Between January 2008 and March 2014, a total of 2219 patients were included in this OCT registry. Among 2219 patients, 1983 patients were excluded for following reasons: (1) 1624 patients with >50% neointimal cross-sectional area (CSA) stenosis; (2) 50 patients treated with bare-metal stents; (4) 83 patients for insufficient demographic data. Consequently, 236 patients who underwent follow-up OCT and had DES-treated lesions with >50% neointimal CSA stenosis at the tightest segment were initially identified. Among these patients, 24 patients were excluded for the following reasons: 13 patients had poor quality of OCT images; 9 underwent OCT evaluation after angioplasty; and 2 had insufficient demographic data. Consequently, 212 patients were finally enrolled in this study. The reasons for follow-up angiography were the following: (1) evidence of myocardial ischemia or symptoms of coronary artery disease (n=179), or (2) planned follow-up angiography for other stent-ed lesions (n=33). At the time of OCT follow-up, 17 patients presented with acute coronary syndrome, 162 presented with stable, and the rest of the patients were asymptomatic. There were 22 patients with stent thrombosis in the Korean multicenter OCT registry; 15 patients with <50% neointimal CSA stenosis and 7 patients with >50% neointimal CSA stenosis. Seven of 22 patients with stent thrombosis were included in the group of 17 patients with acute coronary syndrome in this study. The general inclusion and exclusion criteria for OCT examination were previously reported. The study protocol was approved by the Institutional Review Board of each institute, and written informed consent was obtained from all enrolled patients.

The selection of DES at the time of coronary intervention was at the discretion of the physician. The 212 DES examined in this study were composed of 65 sirolimus-eluting stents (Cyphr, Cordis, Miami Lakes, FL), 36 paclitaxel-eluting stents (Taxus, Boston Scientific, Natick, MA), 40 zotarolimus-eluting stents (Endeavor sprint or Resolute, Medtronic, Santa Rosa, CA), 36 everolimus-eluting stents (Xience, Abbott Vascular, Abbott Park, IL), and 35 bilimus-eluting stents (Nobori, Terumo Corporation, Tokyo, Japan or BioMatrix, Biosensors Inc, Singapore). First-generation DESs are defined as sirolimus- or paclitaxel-eluting stents; second-generation DESs are defined as zotarolimus-, everolimus-, or bilimus-eluting stents. DES implantation was performed using conventional techniques. A minimum dose of 100 mg aspirin and a loading dose of 300 mg clopidogrel were administered ≥12 hours before DES implantation. Unfractionated heparin was administered as an initial bolus of 100 IU/kg, with additional boluses administered during the procedure to achieve an activated clotting time of 250 to 300 seconds during stent implantation. Dual antiplatelet therapy (aspirin and clopidogrel) was recommended to all patients for ≥12 months after DES implantation.

Stent thrombosis was defined according to the recommendations of the Academic Research Consortium. Stent intervention or follow-up OCT evaluation after stent implantation were previously reported. The study protocol was approved by the Institutional Review Board of each institute, and written informed consent was obtained from all enrolled patients. Target-lesion revascularization was defined as a repeat percutaneous intervention or bypass surgery of the target lesions with the following findings: ischemic symptoms or positive stress test and angiographic minimal lumen diameter stenosis ≥50% assessed by quantitative coronary angiographic analysis or an angiographic diameter stenosis ≥70% assessed by quantitative coronary angiographic analysis without either ischemic symptoms or a positive stress test.

Patient history and prescribed medications were investigated through medical record and interview. Laboratory evaluations included total cholesterol, triglycerides, and high-density lipoprotein and low-density lipoprotein (LDL) cholesterol. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Chronic kidney disease was indicated if a patient had <60 mL/min/1.73 m² of estimated glomerular filtration rate.
glomerular filtration rate, which is consistent with the National Kidney Foundation classification stages 3 to 5.15

Quantitative Angiographic Analysis
Quantitative coronary angiography analysis was performed using an offline computerized quantitative coronary angiographic system (CASS system, Pie Medical Imaging, Maastricht, Netherlands) in an independent core laboratory (Cardiovascular Research Center, Seoul, Korea). The minimal lumen diameter and reference diameters of treated coronary lesions were measured in the view with the narrowest lumen and the least amount of foreshortening.

OCT Procedure and Analysis
OCT was performed with either the Model M2 imaging system or the C7-XR imaging systems (LightLab Imaging, Inc., St. Jude Medical, St. Paul, MN). In the former system (Model M2), the occlusion catheter was positioned proximal to the stent and a 0.014 inch wire-type imaging catheter was positioned distal to the stent. During image acquisition, the occlusion balloon (Helios, Avantec Vascular Corp., CA) was inflated to 0.4 to 0.6 atm and lactated Ringer’s solution was infused at 0.5 to 1.0 mL/s. The imaging wire was pulled from distal to proximal with a motorized pull-back system at 1.0 mm/s. The frequency-domain OCT system (Model C7-XR) has been developed to generate frames at much higher rates and, thus, allow faster pull-back speeds. OCT images were acquired at 100 frames/s, whereas the catheter was pulled back at 20 mm/s. A contrast medium was continuously flushed through a guiding catheter at a rate of 4 to 5 mL/s for 3 to 4 seconds. With both systems continuous images were acquired and digitally stored for subsequent analysis.

All OCT images were analyzed using certified offline software (QIvus, Medis medical imaging system, the Netherlands) at a core laboratory (Cardiovascular Research Center, Seoul, Korea) by 2 analysts who were blinded to patient and procedural information. Neointimal CSA was defined as stent CSA–luminal CSA, and the percent neointimal CSA stenosis was defined as \[
\left( \frac{\text{neointimal CSA}}{\text{stent CSA}} \right) \times 100.
\]
OCT images were measured at 1-mm intervals. We separately identified consecutive cross-sections with >50% of percent neointimal CSA stenosis. These cross-sections included the frame with minimal lumen area. Using Simpson’s rule, neointimal volume was calculated as \[
\sum (\text{stent CSA} - \text{lumen CSA}),
\]
and the percentage of neointimal volume was calculated as \[
\frac{\sum (\text{stent CSA} - \text{lumen CSA})}{\sum \text{stent CSA}} \times 100.
\] The volume index (mm 3/mm) was calculated as the volume divided by the measured length.16 Lipid-laden neointima was defined as a diffusely bordered, signal-poor region with overlying signal-rich bands corresponding to fibrous caps.16

Table 1. Baseline Characteristics

<table>
<thead>
<tr>
<th>Clinical Variables</th>
<th>1st-Generation DES (n=101)</th>
<th>2nd-Generation DES (n=111)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>61.5±9.3</td>
<td>61.0±9.7</td>
<td>0.67</td>
</tr>
<tr>
<td>Men</td>
<td>71 (70.3)</td>
<td>86 (77.5)</td>
<td>0.23</td>
</tr>
<tr>
<td>Hypertension</td>
<td>57 (56.4)</td>
<td>63 (56.8)</td>
<td>0.96</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>36 (35.6)</td>
<td>43 (38.7)</td>
<td>0.64</td>
</tr>
<tr>
<td>Current smoker</td>
<td>29 (28.7)</td>
<td>40 (36.0)</td>
<td>0.26</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>11 (10.9)</td>
<td>9 (8.1)</td>
<td>0.49</td>
</tr>
<tr>
<td>Estimated glomerular filtration rate, mL/min/1.73 m²</td>
<td>79.1±22.2</td>
<td>80.3±20.7</td>
<td>0.70</td>
</tr>
<tr>
<td>Acute coronary syndrome</td>
<td>23 (22.8)</td>
<td>38 (34.2)</td>
<td>0.066</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>177.4±41.7</td>
<td>167.9±45.9</td>
<td>0.15</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td>154.7±128.9</td>
<td>139.3±88.0</td>
<td>0.37</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>44.1±11.6</td>
<td>42.9±10.1</td>
<td>0.46</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>108.0±33.8</td>
<td>99.7±40.7</td>
<td>0.16</td>
</tr>
<tr>
<td>Medication at discharge</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>101 (100)</td>
<td>110 (100)</td>
<td>1.0</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>101 (100)</td>
<td>110 (100)</td>
<td>1.0</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>77 (76.2)</td>
<td>81 (73.0)</td>
<td>0.59</td>
</tr>
<tr>
<td>ACE inhibitor or ARB</td>
<td>62 (61.4)</td>
<td>75 (67.6)</td>
<td>0.35</td>
</tr>
<tr>
<td>Statin</td>
<td>85 (84.2)</td>
<td>98 (88.3)</td>
<td>0.38</td>
</tr>
<tr>
<td>Angiographic variables</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Target coronary artery</td>
<td></td>
<td></td>
<td>0.94</td>
</tr>
<tr>
<td>Left anterior descending</td>
<td>64 (63.4)</td>
<td>68 (61.3)</td>
<td>...</td>
</tr>
<tr>
<td>Left circumflex</td>
<td>11 (10.9)</td>
<td>12 (10.8)</td>
<td>...</td>
</tr>
<tr>
<td>Right coronary</td>
<td>26 (25.7)</td>
<td>31 (27.9)</td>
<td>...</td>
</tr>
<tr>
<td>Stent diameter, mm</td>
<td>3.0±0.3</td>
<td>3.1±0.4</td>
<td>0.26</td>
</tr>
<tr>
<td>Total stent length, mm</td>
<td>24.6±5.6</td>
<td>22.9±7.8</td>
<td>0.35</td>
</tr>
<tr>
<td>Reference vessel diameter, mm</td>
<td>2.8±0.5</td>
<td>2.9±0.4</td>
<td>0.12</td>
</tr>
<tr>
<td>Minimal lumen diameter, mm</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-intervention</td>
<td>0.7±0.4</td>
<td>0.8±0.5</td>
<td>0.41</td>
</tr>
<tr>
<td>Post-intervention</td>
<td>2.7±0.4</td>
<td>2.6±0.4</td>
<td>0.73</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD or n (%). ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; DES, drug-eluting stent; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
lipid-laden neointima, thin-cap fibroatheroma was defined as a fibrous cap thickness ≤65 μm at the thinnest part and an angle of the lipid ≥180°.16 Neointimal rupture was a break in the fibrous cap that connected the lumen with the underlying lipid pool.16 The criteria for the diagnosis of neoatherosclerosis were lesions with lipid-laden neointima, neointima with calcification, a thin-cap fibroatheroma-like neointima, or neointimal rupture.4,5 Intraluminal material was defined as visible material inside the lumen.16 The inter- and intraobserver agreement for the evaluation of neointimal tissue in this core laboratory was previously reported.17 Representative images of neoatherosclerosis are shown in Figure 1.

**Statistical Analysis**

Statistical analysis was performed using SPSS (version 18.0.0, SPSS Inc, Chicago, IL). Data are expressed as number (%), mean±standard deviation, or median (interquartile range). Comparisons of categorical data were made using χ² test or the Fisher exact test. Continuous variables were analyzed with Student’s t test or Mann–Whitney U test. Multivariable logistic regression model was applied to determine an independent predictor for neoatherosclerosis. Variables with a P value <0.1 resulting from univariate analysis or traditional cardiovascular risk factors were entered into the multivariable analysis. A P value <0.05 was considered statistically significant.

**Results**

There were no statistically significant differences in baseline clinical and angiographic characteristics in patients who received a first- or second-generation DES (Table 1). Table 2 shows clinical, angiographic, and OCT characteristics between the 2 groups at the time of follow-up OCT. Compared with...
first-generation DES-treated patients, those treated with a second-generation DES showed a lower frequency of acute myocardial infarction (11.9% versus 4.5%, respectively; \( P=0.048 \)) and stent thrombosis (6.9% versus 0%, respectively; \( P=0.005 \)). LDL cholesterol levels >70 mg/dL were less frequently observed in second-generation DES-treated patients (36.0% versus 55.4%; \( P=0.007 \)). Angiotensin-converting enzyme inhibitor/angiotensin receptor blockers were more frequently used in patients treated with second-generation DES (69.4% versus 54.5% in first-generation DES; \( P=0.025 \)). OCT-derived neoatherosclerosis was identified in 27.4% (58/212) of all DES-treated lesions. Neoatherosclerosis was less common in patients treated with second-generation DES (10.8% versus 45.5% in first-generation DES; \( P<0.001 \)). However, the stent age of the second-generation DES was significantly shorter [12.4 (10.6–21.1) months versus 55.4 (34.4–80.4) months; \( P<0.001 \)] and may in part contribute to this observed difference. The frequency of neoatherosclerosis among the zotarolimus-, everolimus-, and biolimus-eluting second-generation DESs was similar (10.0% versus 13.9% versus 8.6%, respectively; \( P=0.80 \)). The frequency of neoatherosclerosis increased with the follow-up period (Figure 2). Neoatherosclerosis was found in 1.6% (1/64) of the lesions under 1 year. On the contrary, neoatherosclerosis was observed in 73.9% (17/23) of the lesions over 7 years. Among the 189 lesions treated by repeat target-lesion revascularization, 8 were treated with a plain balloon, 140 were treated with a drug-eluting balloon, and 41 were treated with a DES.

Table 3 shows the baseline and follow-up clinical, angiographic, and OCT characteristics of patients with and without neoatherosclerosis. At the index procedure, patients with neoatherosclerosis had a higher incidence of both chronic kidney disease and use of first-generation DES and a lower rate of statin treatment. At the follow-up OCT, patients with neoatherosclerosis presented with a higher rate of acute coronary syndrome, stent thrombosis, and an LDL cholesterol level >70 mg/dL. These patients also had a lower rate of statin treatment. The duration of stent age was significantly longer in patients with neoatherosclerosis (66.1 [45.1–87.8] months versus 12.9 [10.5–33.8] months, \( P<0.001 \)).

Predictors for Neoatherosclerosis

Table 4 lists the predictors for neoatherosclerosis after DES implantation. In univariate logistic regression analysis, chronic kidney disease, LDL cholesterol >70 mg/dL at follow-up, usage of first-generation DES, and stent age were significantly associated with neoatherosclerosis. In multivariable analysis, chronic kidney disease (odds ratio [OR], 4.113; 95% confidence interval [CI], 1.086–15.575; \( P=0.037 \)), LDL cholesterol >70 mg/dL at follow-up (OR, 2.532; 95% CI, 1.054–6.084; \( P=0.038 \)), and stent age (OR, 1.710; 95% CI, 1.403–2.084; \( P<0.001 \)) were independent factors for neoatherosclerosis. However, compared with first-generation DESs, second-generation DESs were not associated with neoatherosclerosis after adjusting for cardiovascular risk factors. Notably, no individual subtype of second-generation DES was associated with neoatherosclerosis (OR, 0.384; 95% CI, 0.092–1.600; \( P=0.19 \) in zotarolimus-; OR, 0.844; 95% CI, 0.221–3.221; \( P=0.80 \) in everolimus-; and OR, 0.475; 95% CI, 0.097–2.341; \( P=0.36 \) in biolimus-eluting stent).

Discussion

This study shows that neoatherosclerosis was observed in about a quarter of all DES-treated lesions with >50% percent neointimal CSA stenosis. The incidence of neoatherosclerosis increases with stent age. The clinical presentation of neoatherosclerosis was significantly associated with the onset of acute coronary syndrome or stent thrombosis at follow-up. Although neoatherosclerosis was less frequently detected in second-generation DES in univariate analysis, multivariable analysis revealed that chronic kidney disease, an LDL cholesterol level of >70 mg/dL at follow-up, and stent age were each an independent predictor for neoatherosclerosis. DES type
Neoatherosclerosis in DES

Previous studies have shown that neoatherosclerosis was detected earlier in DES-treated lesions compared with bare-metal stent-treated lesions.2–7 In the present era where the use of the DES is so common, this observation may raise the concern that atherosclerotic changes inside DES-neointima may facilitate the sudden onset of an adverse cardiac event (ie, stent thrombosis) during the extended follow-up period. Compared with the first-generation DES, the second-generation DES has significantly improved, in many regards. They are coated with new antiproliferative drugs, constructed with a biodegradable, and designed in a thin stent strut. These properties were associated with better strut coverage of second-generation DES18 and anticipated the enhanced property regarding in-stent neoatherosclerosis. However, most of published OCT or autopsy studies did not compare the in-stent neoatherosclerosis between first- and second-generation DES because of smaller number of second-generation DES-treated lesions.2–7 A recent autopsy study revealed the superiority of cobalt-chromium everolimus-eluting stent over first-generation DES in terms of vascular inflammation, fibrin deposition, and stent thrombosis.18 Nevertheless, the frequency of neoatherosclerosis was similar between 2 devices.18 This is consistent with

### Table 3. Baseline and Follow-Up Characteristics According to the Presence of Neoatherosclerosis

<table>
<thead>
<tr>
<th></th>
<th>Neoatherosclerosis</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes (n=58)</td>
<td>No (n=154)</td>
</tr>
<tr>
<td>Baseline characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>61.7±10.1</td>
<td>61.1±9.3</td>
</tr>
<tr>
<td>Male</td>
<td>43 (74.1)</td>
<td>114 (74.0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>35 (60.3)</td>
<td>85 (55.2)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>20 (34.5)</td>
<td>59 (38.3)</td>
</tr>
<tr>
<td>Current smoker</td>
<td>15 (25.9)</td>
<td>49 (31.8)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>11 (19.0)</td>
<td>9 (5.8)</td>
</tr>
<tr>
<td>Estimated glomerular filtration rate, mL/min/1.73 m²</td>
<td>72.7±27.4</td>
<td>80.5±22.5</td>
</tr>
<tr>
<td>Acute coronary syndrome</td>
<td>20 (34.5)</td>
<td>41 (26.6)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>175.3±38.5</td>
<td>171.2±46.1</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td>165.7±158.1</td>
<td>139.5±84.2</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>44.3±12.0</td>
<td>43.1±10.4</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>111.1±36.8</td>
<td>100.8±37.8</td>
</tr>
<tr>
<td>Medication at discharge</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>45 (77.6)</td>
<td>113 (73.4)</td>
</tr>
<tr>
<td>ACE inhibitor or ARB</td>
<td>35 (60.3)</td>
<td>102 (66.2)</td>
</tr>
<tr>
<td>Statin</td>
<td>46 (79.3)</td>
<td>137 (89.0)</td>
</tr>
<tr>
<td>Target coronary artery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left anterior descending</td>
<td>35 (60.3)</td>
<td>97 (63.0)</td>
</tr>
<tr>
<td>Left circumflex</td>
<td>8 (13.8)</td>
<td>15 (9.7)</td>
</tr>
<tr>
<td>Right coronary</td>
<td>15 (25.9)</td>
<td>42 (27.3)</td>
</tr>
<tr>
<td>Stent type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>First-generation DES</td>
<td>46 (79.3)</td>
<td>55 (35.7)</td>
</tr>
<tr>
<td>Second-generation DES</td>
<td>12 (20.7)</td>
<td>99 (64.3)</td>
</tr>
<tr>
<td>Reference vessel diameter, mm</td>
<td>2.9±0.4</td>
<td>2.9±0.4</td>
</tr>
<tr>
<td>Minimal lumen diameter, mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preintervention</td>
<td>0.8±0.4</td>
<td>0.7±0.5</td>
</tr>
<tr>
<td>Postintervention</td>
<td>2.7±0.4</td>
<td>2.6±0.4</td>
</tr>
<tr>
<td>Follow-up characteristics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, y</td>
<td>69.5 (60.7–74.4)</td>
<td>62.5 (56.0–70.9)</td>
</tr>
<tr>
<td>Clinical presentation of acute coronary syndrome at follow-up</td>
<td>11 (19.0)</td>
<td>6 (3.9)</td>
</tr>
<tr>
<td>Clinical presentation of stent thrombosis at follow-up</td>
<td>7 (12.1)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>147.0±36.5</td>
<td>136.9±33.2</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
<td>123.2±37.9</td>
<td>111.2±59.2</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>43.2±12.4</td>
<td>43.6±10.5</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>79.6±29.7</td>
<td>70.5±26.6</td>
</tr>
<tr>
<td>LDL cholesterol &gt;70 mg/dL</td>
<td>38 (65.5)</td>
<td>57 (37.0)</td>
</tr>
<tr>
<td>Medication at follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>41 (70.7)</td>
<td>111 (72.1)</td>
</tr>
<tr>
<td>ACE inhibitor or ARB</td>
<td>32 (55.2)</td>
<td>100 (64.9)</td>
</tr>
<tr>
<td>Statin</td>
<td>48 (82.8)</td>
<td>141 (91.6)</td>
</tr>
<tr>
<td>Stent age, months</td>
<td>66.1 (45.1–87.8)</td>
<td>12.9 (10.5–33.8)</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD, median (interquartile range) or n (%). ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; DES, drug-eluting stent; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.

(Continued)
the results in the current study. The current study investigated the largest number of second-generation DES-treated lesions compared with the previous studies and also directly compared second- with first-generation DES. A preclinical study reported that cobalt-chromium everolimus-eluting stent shows greater expression of platelet endothelial cell adhesion molecule-1 versus first-generation DES. However, compared with bare-metal stent, endothelial maturation without impairment of endothelial barrier function is still insufficient in cobalt-chromium everolimus-eluting stent, as well as first-generation DES. Although the second-generation DES failed to improve in-stent neoatherosclerosis compared with the first-generation DES, a large registry data showed the superiority of second-generation DES regarding stent thrombosis. Although improved strut coverage of second-generation DES may reduce the occurrence of late stent thrombosis by poor strut coverage, it seems still insufficient for second-generation DES to inhibit the development of neoatherosclerosis.

Predictors for Neoatherosclerosis
Previous studies suggested possible predictors for in-stent neoatherosclerosis. According to pathological study by Nakazawa et al, younger age, longer implant durations, usage of first-generation DES (compared with bare-metal stent), and underlying unstable plaques were independent determinants for neoatherosclerosis. Using OCT, Yonetsu et al suggested that ≥48 months of stent age, all subtypes of DES (compared with bare-metal stent), current smoking, chronic kidney disease, and use of angiotensin-converting enzyme inhibitors/angiotensin receptor blocker were risk factors. Ali and colleagues reported that baseline serum creatinine and high-density lipoprotein cholesterol tended to be associated with neoatherosclerosis in addition to prior usage of DES. In the present study, 2 clinical factors, LDL cholesterol >70 mg/dL at follow-up and chronic kidney disease, are related to neoatherosclerosis.

The association between renal dysfunction and in-stent neoatherosclerosis was founded by previous studies. The present study supports these data and additionally shows this association is relevant in a relatively large burden of neointima as well. As possible explanations, previous reports have suggested that oxidative stress and inflammation might mediate the observed high frequency of cardiovascular disease in patients with chronic kidney disease. These systemic responses may also lead to the atherosclerotic changes observed inside neointima over the course of an extended follow-up period. Neoatherosclerosis may be associated with incomplete or delayed endothelization of the DES. Because the endothelium generally acts as a barrier against the excessive uptake of circulating lipids, prolonged exposure to even a modest level of LDL cholesterol may potentially lead to the accumulation of lipids inside the neointima with incompetent endothelium. Higher levels of LDL cholesterol have been regarded as an important risk factor for the development of atherosclerosis in de novo coronary lesions. This is the first study to report that there may be a significant relationship between neoatherosclerosis and higher levels of LDL cholesterol at follow-up even in DES-treated lesions.

Study Limitations
Because this is a retrospective registry study, only patients with OCT evaluation at follow-up were included in the present study. The use of particular type of DES was at the discretion of the physician. The indications for follow-up OCT were different from myocardial ischemia to planned follow-up angiography. Thus, selection bias may have affected the results. Unmeasured confounders (ie, missing of cardiovascular events or death in the interim before an OCT follow-up) can exit and may influence the results of present study. Although the detection of lipid-rich plaque using OCT has been validated by histopathology studies, the analysis of neointimal pattern is limited. There is no absolute
consensus among publications as to the OCT criteria for neoatherosclerosis, and this might affect the incidence of this phenomenon. The time interval from DES implantation to follow-up, OCT was different between first- and second-generation DES; different stent age (longer time interval in first-generation DES versus shorter time interval in second-generation DES) may affect the statistical analysis in multivariable logistic regression analysis even after control for stent age. Because stent type is unavoidable confounded by stent age, there might be no statistical significance of stent type in multivariable logistic regression analysis. In addition, the statistical analysis may have limited ability to control for all necessary confounders and to detect an OR as low as 0.05 because small size of study populations. Therefore, further studies with larger number of DES-treated patients and comparable stent age are required. The study patients in our prior publication were included in the analysis of this study.

Conclusions
Neoatherosclerosis accounts for about a quarter of DES-treated lesions. Using multivariable logistic regression analysis, the presence of chronic kidney disease, LDL cholesterol of >70 mg/dL at follow-up, and stent age are independently associated with neoatherosclerosis. The use of first- or second-generation DES held no predictive value of neoatherosclerosis. These findings suggest that the continuous protection against cardiovascular risks may suppress neoatherosclerotic changes and subsequently avoid the clinical deterioration related to neoatherosclerosis during the extended follow-up period after DES implantation.

Sources of Funding
This study was supported by a grant from the Korea Healthcare Technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (Nos. A085012 and A102064), and a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No. A085136), and the Cardiovascular grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (No. A085136), and the Cardiovascular Research Center, Seoul, Korea.

Disclosures
None.

References


Optical Coherence Tomographic Observation of In-Stent Neoatherosclerosis in Lesions With More Than 50% Neointimal Area Stenosis After Second-Generation Drug-Eluting Stent Implantation


Circ Cardiovasc Interv. 2015;8:e001878
doi: 10.1161/CIRCINTERVENTIONS.114.001878
Circulation: Cardiovascular Interventions is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-7640. Online ISSN: 1941-7632

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circinterventions.ahajournals.org/content/8/2/e001878

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation: Cardiovascular Interventions can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation: Cardiovascular Interventions is online at:
http://circinterventions.ahajournals.org//subscriptions/